Hey there,
Sometimes a biotech story is big because of its science. Sometimes it's big because of its strategy.
This one has both.
On the science side: a next-generation approach to blocking cancer's "Don't Eat Me" signal, designed to unleash the immune system without the side effects that have doomed past attempts.
On the strategy side: an eye-opening plan to create a $500 million digital asset investment vehicle — an unusual move for a biotech, aimed at securing massive, non-dilutive funding.
Big pharma has paid billions for similar technologies. But few companies have entered the race with both a potentially safer therapy and a bold financial game plan.
Add in a small share float, human trials on the horizon, and the potential for M&A interest if early data delivers — and you have a biotech play that could move fast in the right conditions.
The combination of a medical breakthrough and capital innovation doesn't come around often.
Find out why some traders are already getting positioned.
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
This message is a PAID ADVERTISEMENT for Liminatus Pharma Inc (NASDAQ:LIMN) from Market Jar Media Inc. StockEarnings, Inc. has received a fixed fee of $25000 from Market Jar Media Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between August 14, 2025 and August 21, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Liminatus Pharma Inc (NASDAQ:LIMN) or Market Jar Media Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Liminatus Pharma Inc (NASDAQ:LIMN) on TradingWhisperer website for additional information about the relationship between Market Jar Media Inc and Liminatus Pharma Inc (NASDAQ:LIMN).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
